UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September 2025
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Purple Biotech
On September 3, 2025, Purple Biotech Ltd. (the “Company”
or the “Registrant”) issued a press release “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel
Tri-Specific Antibody Targeting TROP2”, which is attached hereto as Exhibit 99.1.
| Exhibit |
|
|
| 99.1 |
|
Purple Biotech
Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| September 3, 2025 |
PURPLE BIOTECH LTD. |
| |
|
| |
By: |
/s/ Gil Efron |
| |
|
Gil Efron |
| |
|
Chief Executive Officer |
